✦ LIBER ✦

Significant impact of cutaneous T-cell lymphoma on patients' quality of life : Results of a 2005 National Cutaneous Lymphoma Foundation Survey

✍ Scribed by Marie-France Demierre; Stephanie Gan; Judy Jones; Donald R. Miller

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 92 KB
Volume: 107
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.22252

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

RESEARCH REPORT Bexarotene capsules and

RESEARCH REPORT Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: Results of the Australian patients treated on phase II trials

✍ H Miles Prince; Christopher McCormack; Gail Ryan; Christopher Baker; Harvey Rots 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 54 KB

## SUMMARY Bexarotene (Targretin^®^, LGD1069) is a novel synthetic retinoid analogue that binds selectively to retinoid X receptors. We describe eight previously treated patients who entered phase II international multicentre studies examining the role of bexarotene in cutaneous T‐cell lymphoma. Pa

Results of a Phase II trial of oral bexa

Results of a Phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma

✍ David J. Straus; Madeleine Duvic; Timothy Kuzel; Steven Horwitz; Marie-France De 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

## Abstract ## BACKGROUND. Bexarotene is one of the most active single agents for the treatment of recurring or refractory cutaneous T‐cell lymphoma (CTCL). Interferon alfa has also been used for many years as an effective treatment for this disease. The results in recent case reports of the combi